期刊
JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY A-CHEMISTRY
卷 314, 期 -, 页码 143-154出版社
ELSEVIER SCIENCE SA
DOI: 10.1016/j.jphotochem.2015.08.024
关键词
Pluronic; Micelles; Photodynamic Therapy; Benzoporphyrin; Cancer
资金
- Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)
- UGF/SETI-Parana
- Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) [BEX 14036/13-14]
In this study we attempted to develop Pluronic micelles delivering the photodynamic therapy photosensitizers benzoporphyrin derivatives (BPD). The BPD A-ring (BPDMA or Verteporfin (R), the active drug of FDA/USA approved Visudyne (R)), its regioisomer ring-B (BPDMB, not used in Visudyne (R) formulation due its poor solubility) and a BPDMA/BPDMB mixture (BPD-Mixt) were formulated in Pluronic P123 or F127 as well as P123/F127 mixed micelles at two different mass ratios. P123/F127 presented the lowest critical micelle concentration showing high stability due synergistic aggregation of P123 and F127. Mixed micelles allowed the encapsulation of BPD as monomers enhancing their photophysical properties and stability during time even under diluted conditions. High loading was attributed to the strong hydrophobic affinity of BPD for micelle core especially in the binary system due synergistic aggregation of P123 and F127 demonstrating the high potential of these micelles to encapsulate hydrophobic drugs. The in vitro assays showed a photo-activity of BPD-Mixt comparable to that of BPDMA against HeLa and A549 cancer cells under red light. The use of BPD-mixed formulations avoids the complex separation steps of these regioisomers and implies in cost reduction. The proposed system allies costs reduction and photodynamic efficiency, which stimulates further development on this nanosystem and may be of clinical interest for cancer PDT. (C) 2015 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据